Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study-Reference-Cited by-同舟云学术

Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study

Published:2019-06-05 Issue:8 Volume:46 Page:662-671
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Mihara Ryosuke¹^ORCID,Kabashima Kenji²,Furue Masutaka³^ORCID,Nakano Miwa¹,Ruzicka Thomas⁴

Affiliation:

1. Chugai Pharmaceutical Co. Ltd TokyoJapan

2. Graduate School of Medicine Kyoto University KyotoJapan

3. Graduate School of Medical Science Kyushu University Fukuoka Japan

4. Ludwig‐Maximilian University Munich Germany

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.14934

Reference34 articles.

1. Guidelines of care for the management of atopic dermatitis

2. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

3. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

4. A sensory neuron–expressed IL-31 receptor mediates T helper cell–dependent itch: Involvement of TRPV1 and TRPA1

5. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials;The Lancet;2024-08

2. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond;Expert Opinion on Biological Therapy;2024-06-02

3. Emerging treatments for itch in atopic dermatitis: A review;Journal of the American Academy of Dermatology;2023-08

4. Rôle de l’interleukine 31, une cytokine neuro-immune, dans le prurit et au-delà;Annales de Dermatologie et de Vénéréologie - FMC;2023-04

5. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries;British Journal of Dermatology;2023-03-27